The Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R21 Clinical Trial Optional) from the National Institutes of Health (NIH) supports exploratory and innovative research applications focused on the neurological and neuropsychiatric manifestations of COVID-19 (neuro-COVID) and Post-Acute Sequelae of SARS-CoV-2 Infection (neuro-PASC) and on the effect of COVID-19 on pre-infection neurologic conditions. Applications investigating the pathophysiology and mechanisms of neuro-COVID and neuro-PASC and neurologically-focused human subjects research, as well as those proposing studies of scientifically compelling pathways to prevent the development of neuro-PASC or to accelerate the development of effective treatments forPASC-related neurological complications are of particular interest. This is an R21 grant application and does not need to have extensive background material or preliminary information. Applications are open to researchers in the USA. The grant provides 275,000 USD for up to 2 years.
Funding opportunity number: RFA-NS-23-022.
Letters of intent are due on January 2, 2024.
Applications close on February 2, 2024.
February 2, 2024